Population
Patients with systemic sclerosis and healthy donors
Comparison
Exogenous Angiotensin II (in vitro) vs Normal subjects/fibroblasts; untreated cells
Design
Preclinical
Authors
Loading...
Hypothesis-generating for AT1 antagonism in SSc fibrosis; human trials needed before any clinical consideration.
Aberrant Angiotensin II production and AT1 receptor activation contribute to tissue fibrosis in systemic sclerosis, suggesting AT1 receptor antagonists as a potential therapeutic strategy.
Kawaguchi et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: